Assignment of the orphan nuclear receptor Nurr1 by NMR.
Michiels P, Atkins K, Ludwig C, Whittaker S, van Dongen M, Günther U
This study mapped the structure of Nurr1, a protein linked to Parkinson's and schizophrenia, using advanced NMR techniques. The flexible regions near its ligand-binding site suggest challenges in drug design but also highlight potential targets for future therapies.
- Nurr1 structure was mapped using NMR spectroscopy
- Flexible regions near ligand-binding site may affect drug development
- Hydrophobic residues stabilize the ligand-binding pocket
- Findings may guide future treatments for NR4A2-related disorders
Roles of db-cAMP, IBMX and RA in aspects of neural differentiation of cord blood derived mesenchymal-like stem cells.
Tio M, Tan KH, Lee W, Wang TT, Udolph G
Human umbilical cord blood mesenchymal stem cells can develop into cells that make dopamine, a key feature of Parkinson’s disease, and specific chemicals in the growth medium help control the genes and proteins involved in this process. The study identifies how certain signaling pathways may influence dopamine-producing cell development, which could inform future therapies.
- Cord blood stem cells can become dopamine-making cells
- Key genes like Nurr1 and TH are activated during differentiation
- Chemicals in the growth medium regulate dopamine-related proteins
- Signaling pathways may control dopamine cell maturation
- Findings could guide future treatments for dopamine loss
Long-term culture and differentiation of CNS precursors derived from anterior human neural rosettes following exposure to ventralizing factors.
Colleoni S, Galli C, Giannelli SG, Armentero MT, Blandini F, Broccoli V, Lazzari G
This study shows that human stem cells can be guided to become long-lasting, self-renewing precursors that develop into dopaminergic neurons—cells lost in Parkinson’s disease. These precursors can be grown in the lab for long periods and successfully integrate and mature into functional dopamine-producing neurons when transplanted into rats with Parkinson’s-like symptoms.
- Human stem cells become dopaminergic neuron precursors using key signaling factors
- These precursors grow long-term and turn into functional dopamine neurons
- Transplanted cells survived and matured in Parkinson’s model rats
- Findings support potential for cell therapies in dopamine-related disorders
- Provides a scalable source of human dopaminergic neurons for research and treatment
Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis.
Gilli F, Lindberg RL, Valentino P, Marnetto F, Malucchi S, Sala A, Capobianco M, di Sapio A, Sperli F, Kappos L, Calogero RA, Bertolotto A
Pregnancy reduces multiple sclerosis (MS) relapses by naturally adjusting the activity of key inflammation-related genes, including NR4A2, which helps restore immune balance within the first trimester. Women who relapsed during pregnancy showed delayed normalization of these gene expressions, suggesting that timing of immune regulation matters.
- Pregnancy reduces MS relapses by resetting immune gene activity
- NR4A2 is one of seven genes that normalize during pregnancy
- Relapses during pregnancy linked to delayed gene expression recovery
- Immune balance returns within first trimester of pregnancy
- Findings may guide new treatments for MS
In vitro and in vivo enhanced generation of human A9 dopamine neurons from neural stem cells by Bcl-XL.
Courtois ET, Castillo CG, Seiz EG, Ramos M, Bueno C, Liste I, Martínez-Serrano A
Boosting the protein Bcl-XL helps human stem cells grow into healthy dopamine neurons that match the type lost in Parkinson's disease, both in lab tests and in animal models. These improved neurons survive, integrate, and reduce motor symptoms in rats, suggesting a promising path for cell therapies.
- Bcl-XL boosts production of correct dopamine neurons
- Neurons match those in the brain's substantia nigra
- Improved survival and function in animal models
- Reduces unwanted glial cell formation
- Supports development of Parkinson's cell therapies
Regulation of aldosterone synthase by activator transcription factor/cAMP response element-binding protein family members.
Nogueira EF, Rainey WE
The study shows that proteins called ATF/CREB and NURR1 (NR4A2) work together to control the production of aldosterone in adrenal cells, which is important for understanding how the body regulates salt and blood pressure.
- ATF/CREB and NURR1 (NR4A2) regulate aldosterone production
- These proteins bind to the gene that makes aldosterone
- Blocking these proteins reduces aldosterone output
- NURR1 works with ATF/CREB to boost gene activity
- Findings may help treat disorders of aldosterone levels
Delayed dopaminergic neuron differentiation in Lrp6 mutant mice.
Castelo-Branco G, Andersson ER, Minina E, Sousa KM, Ribeiro D, Kokubu C, Imai K, Prakash N, Wurst W, Arenas E
Lrp6 is needed for timely development of dopamine-producing brain cells in mouse embryos, and its absence delays the formation of these neurons and affects midbrain shape, suggesting a role in early brain development relevant to disorders like NR4A2-related syndrome.
- Lrp6 helps start dopamine neuron development in the midbrain
- Without Lrp6, dopamine neurons form later and in fewer numbers
- Midbrain shape is also affected in Lrp6-deficient embryos
- Lrp6 is active during early brain formation
- Findings may inform how NR4A2-related brain development issues arise
Identification of microRNAs regulated by activin A in human embryonic stem cells.
Tsai ZY, Singh S, Yu SL, Kao LP, Chen BZ, Ho BC, Yang PC, Li SS
Activin A alters microRNA levels in human embryonic stem cells, affecting genes linked to cell development and function, including NR4A2, which is relevant to NR4A2-related syndrome. These changes may influence cell behavior and could inform future therapies.
- Activin A changes microRNA levels in stem cells
- NR4A2 is among genes affected by these microRNAs
- MicroRNA changes may influence cell development
- Findings could help understand NR4A2-related biology
- Potential implications for stem cell-based therapies
Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons.
Kadkhodaei B, Ito T, Joodmardi E, Mattsson B, Rouillard C, Carta M, Muramatsu S, Sumi-Ichinose C, Nomura T, Metzger D, Chambon P, Lindqvist E, Larsson NG, Olson L, Björklund A, Ichinose H, Perlmann T
Nurr1 is essential for keeping midbrain dopamine neurons healthy, both during development and in adulthood. Losing Nurr1 causes dopamine neurons to degenerate, especially in the brain region most affected in Parkinson's disease.
- Nurr1 maintains dopamine neurons throughout life
- Without Nurr1, neurons lose dopamine and die
- Substantia nigra neurons are most vulnerable
- Nurr1 loss mimics Parkinson's disease changes
- Nurr1 dysfunction may cause neurodegeneration
Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease.
Friling S, Bergsland M, Kjellander S
Activating the Retinoid X Receptor (RXR) protects dopamine neurons from damage in models of Parkinson's disease, including exposure to toxins and low oxygen. Mouse stem cells can be used to grow dopamine neurons for testing potential treatments, offering a reliable lab model.
- RXR activation protects dopamine neurons from Parkinson's-like damage
- The effect works against toxin and low-oxygen stress, not all types of cell damage
- Stem cell-derived dopamine neurons provide a practical lab model
- This suggests RXR as a promising target for new Parkinson's treatments
The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives.
Wan F, Lenardo MJ
This paper reviews how NF-kappaB, a key regulator of immune and inflammatory responses, is controlled inside the nucleus. It identifies several nuclear proteins, including Nurr1, that fine-tune NF-kappaB's activity, offering new insights into potential therapeutic targets.
- NF-kappaB's activity is regulated inside the nucleus by specific proteins
- Nurr1 is one of several newly identified nuclear regulators of NF-kappaB
- These nuclear mechanisms offer new paths for treating NF-kappaB-related diseases
- Understanding nuclear signaling improves potential for targeted therapies
Cell density is a critical determinant of aromatase expression in adipose stromal cells.
Ghosh S, Hu Y, Li R
High cell density in fat tissue cells increases estrogen production, which may raise breast cancer risk in obese postmenopausal women. This effect is linked to reduced levels of NR4A2 (Nurr1), a gene important for regulating metabolism and inflammation.
- Fat cell density boosts estrogen-making enzyme activity
- NR4A2 (Nurr1) levels drop when fat cells become crowded
- Low NR4A2 is tied to higher estrogen production
- This may explain higher breast cancer risk in obesity
- Cell density effects vary between people
Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway.
Chung S, Leung A, Han BS, Chang MY, Moon JI, Kim CH, Hong S, Pruszak J, Isacson O, Kim KS
This study identifies a key genetic loop involving Wnt1 and Lmx1a that drives the development of midbrain dopamine neurons, which are lost in Parkinson's disease. The findings show that combining Wnt and SHH signaling pathways boosts the creation of these neurons from stem cells, offering a potential strategy for cell-based therapies.
- Wnt1 and Lmx1a form a self-sustaining loop that controls dopamine neuron development
- Lmx1a works with Otx2, Nurr1, and Pitx3 to guide neuron formation
- Activating both Wnt and SHH pathways together improves stem cell conversion to dopamine neurons
- This process mirrors natural brain development and could inform cell replacement therapies
Ontogenetic expression of dopamine-related transcription factors and tyrosine hydroxylase in prenatally stressed rats.
Katunar MR, Saez T, Brusco A, Antonelli MC
Prenatal stress in rats disrupts the normal development of dopamine-producing brain regions, especially the ventral tegmental area, leading to lasting changes in key genes and enzymes involved in dopamine production. These changes may underlie long-term behavioral issues related to motivation, emotion, and reward, similar to those seen in human neuropsychiatric disorders.
- Prenatal stress alters dopamine-related gene expression in rat brains
- Nurr1 increases and Pitx3 changes over time in the reward pathway
- Tyrosine hydroxylase levels drop early but recover later
- Changes are most pronounced in the ventral tegmental area
- These disruptions may lead to lifelong emotional and behavioral problems
Involvement of nuclear factor-kB and Nurr-1 in cytokine-induced transcription of proopiomelanocortin gene in AtT20 corticotroph cells.
Takayasu S, Iwasaki Y, Nigawara T, Asai M, Yoshida M, Kageyama K, Suda T
Proinflammatory cytokines activate the POMC gene, which controls stress hormone production, by turning on the NF-kappaB and Nurr-1 proteins. Nurr-1 acts as a bridge between immune signals and the body's stress response, and blocking NF-kappaB stops this activation.
- Cytokines boost POMC gene expression via NF-kappaB and Nurr-1
- Nurr-1 is turned on by NF-kappaB in response to inflammation
- Blocking NF-kappaB stops cytokine-driven POMC activation
- Nurr-1 links immune signals to the stress hormone system
- This pathway may be a target for treating stress-related symptoms
Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor.
Gibrat C, Bousquet M, Saint-Pierre M, Lévesque D, Calon F, Rouillard C, Cicchetti F
Cystamine protects brain cells in mice exposed to a toxin that mimics Parkinson's disease, mainly by boosting levels of BDNF, a brain-protective protein. The lowest dose tested (10mg/kg) was most effective, suggesting a precise dosing window for potential benefit.
- Cystamine protects dopamine neurons in mouse models of Parkinson's
- Low dose (10mg/kg) boosts BDNF in the brain's dopamine region
- Protection correlates with increased BDNF, not TrkB or Hsp70
- 21-day treatment prevented neuron loss and Nurr1 reduction
- BDNF upregulation appears central to cystamine's protective effect
Brn3a and Nurr1 mediate a gene regulatory pathway for habenula development.
Quina LA, Wang S, Ng L, Turner EE
The habenula, a brain region linked to mood and reward, develops through a gene pathway involving Brn3a and Nurr1 (NR4A2), with Nurr1 acting downstream of Brn3a to control key genes for proper brain wiring. This pathway is essential for neurons to connect correctly to their targets in the midbrain.
- Nurr1 (NR4A2) is part of a gene pathway guiding habenula development
- Nurr1 works downstream of Brn3a to control brain wiring genes
- Disruption of this pathway prevents proper nerve connections
- The habenula's unique gene profile depends on this regulatory network
- Findings reveal a direct molecular mechanism relevant to NR4A2-related disorders
Differentiation of mouse Neuro 2A cells into dopamine neurons.
Tremblay RG, Sikorska M, Sandhu JK, Lanthier P, Ribecco-Lutkiewicz M, Bani-Yaghoub M
Treating mouse Neuro 2A cells with dibutyryl cAMP (dbcAMP) significantly increases their production of dopamine neurons, making this a reliable method to generate these cells for research. The effect depends on cAMP signaling and is blocked by retinoic acid.
- dbcAMP boosts dopamine neuron formation in N2a cells
- Only dbcAMP increases TH and dopamine levels
- cAMP/CREB pathway drives dopamine neuron development
- Retinoic acid blocks the dbcAMP effect
- Method is fast and useful for drug testing
NR4A orphan nuclear receptors influence retinoic acid and docosahexaenoic acid signaling via up-regulation of fatty acid binding protein 5.
Volakakis N, Joodmardi E, Perlmann T
NR4A2 (Nurr1) increases levels of a protein called FABP5, which helps control how the body uses retinoic acid and DHA—two substances important for brain development and function. This suggests NR4A2 may influence key signaling pathways relevant to neurological health.
- NR4A2 boosts FABP5, a protein that handles fatty acids and signaling molecules
- FABP5 helps activate pathways linked to brain development and function
- NR4A2 may enhance the effects of retinoic acid and DHA through FABP5
- Other NR4A family members also increase FABP5
- This could affect how brain cells respond to nutrients and signals
Organization of the human embryonic ventral mesencephalon.
Nelander J, Hebsgaard JB, Parmar M
Key genes that guide the development of dopamine-producing neurons in the human brain are active in the same patterns and locations as in mice, suggesting similar developmental processes across species. This supports the idea that findings from animal studies can inform our understanding of human brain development and disorders like NR4A2-related syndrome.
- Human VM development mirrors mouse patterns
- NR4A2-related genes like NURR1 are active in dopamine neurons
- Key regulators appear in correct timing and location
- Findings support animal models for human neurodevelopment
- Insight into dopamine neuron formation in humans
Neuroinflammation in Parkinson's disease.
Lee JK, Tran T, Tansey MG
Neuroinflammation contributes to the progressive loss of dopamine-producing neurons in Parkinson's disease, driven by activated immune cells and inflammatory signals in the brain. This review highlights how inflammation interacts with key Parkinson's-related genes, including Nurr1, to worsen neurodegeneration.
- Inflammation damages dopamine neurons in Parkinson's disease
- Microglia and immune cells drive brain inflammation
- Nurr1 interacts with inflammation to worsen neuron loss
- Systemic inflammation can trigger brain immune responses
- Anti-inflammatory drugs may reduce Parkinson's risk
Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons.
Hwang DY, Hong S, Jeong JW, Choi S, Kim H, Kim J, Kim KS
Pitx3 is a key regulator of dopamine neurons in the brain, directly controlling genes that manage dopamine storage and recycling. Without Pitx3, these critical functions fail, which may contribute to the loss of dopamine neurons seen in Parkinson's disease.
- Pitx3 controls dopamine storage and reuptake genes
- Loss of Pitx3 disrupts dopamine neuron function
- Pitx3 works with Nurr1 to support dopamine neurons
- This pathway is relevant to Parkinson's disease
- May inform future treatments for dopamine disorders
Expression pattern of NuIP gene in adult mouse brain.
Luo Y, Sarabi SA, Backman C, Shan L, Hoffer B, Federoff H
NuIP is highly expressed in key brain regions involved in movement, memory, and cognition, particularly in dopamine-producing neurons of the midbrain, suggesting it plays a role in brain functions relevant to NR4A2-related syndrome. It is found in neurons throughout the brain, including areas critical for motor control and higher thinking, and may influence how these neurons function.
- NuIP is abundant in midbrain dopamine neurons linked to movement and behavior
- It is found in brain areas tied to memory and learning, like the hippocampus and cortex
- NuIP is mostly in neurons but also appears in some glial cells
- Its expression pattern suggests roles in motor control and cognitive functions
- NuIP may modulate Nurr1 activity, which is central to NR4A2-related disorders
Identification of NR4A2 as a transcriptional activator of IL-8 expression in human inflammatory arthritis.
Aherne CM, McMorrow J, Kane D, FitzGerald O, Mix KS, Murphy EP
NR4A2 drives the production of IL-8, a key inflammatory protein, in human joint tissue during inflammatory arthritis. This process is linked to TNF-alpha signaling and may be reduced by methotrexate treatment.
- NR4A2 boosts IL-8, a major inflammatory signal, in joint cells
- NR4A2 works with NF-kappaB to increase inflammation
- Methotrexate lowers both NR4A2 and IL-8 in patients
- NR4A2’s effect happens without binding DNA directly
- Targeting NR4A2 could reduce joint inflammation
Generation of dopamine neurons with improved cell survival and phenotype maintenance using a degradation-resistant nurr1 mutant.
Jo AY, Kim MY, Lee HS, Rhee YH, Lee JE, Baek KH, Park CH, Koh HC, Shin I, Lee YS, Lee SH
Using a modified version of the Nurr1 protein that resists breakdown, researchers created dopamine neurons that survive longer and maintain their function better after transplantation. This approach improves the potential for treating Parkinson's disease and may inform therapies for NR4A2-related syndromes.
- A modified Nurr1 protein resists degradation
- Dopamine neurons survive longer after transplant
- Improved function and stability in lab and animal models
- Offers a potential path for treating NR4A2-related conditions
Subtype specification of GABAergic amacrine cells by the orphan nuclear receptor Nr4a2/Nurr1.
Jiang H, Xiang M
Nr4a2 is a key gene that helps determine the identity of certain retinal cells called GABAergic amacrine cells, and its function is similar in the brain and eye. In mice, losing Nr4a2 causes the loss of specific retinal cell types, including dopamine-producing cells, while increasing others. This suggests Nr4a2 is essential for forming the correct types of retinal neurons.
- Nr4a2 controls the development of specific retinal cells
- Loss of Nr4a2 leads to missing dopamine and other retinal cells
- Nr4a2 helps determine cell identity in the retina
- Nr4a2 works with other known retinal genes
- Findings may help understand NR4A2-related disorders
A novel combination of factors, termed SPIE, which promotes dopaminergic neuron differentiation from human embryonic stem cells.
Vazin T, Becker KG, Chen J, Spivak CE, Lupica CR, Zhang Y, Worden L, Freed WJ
A combination of four proteins—SDF-1, PTN, IGF2, and EFNB1—can guide human stem cells to become functional dopamine-producing brain cells, mimicking a natural process without using animal cells. This method may help develop treatments for Parkinson’s and related disorders, including those involving NR4A2/NURR1 dysfunction.
- SPIE proteins drive stem cells into dopamine neurons
- Generated neurons show key brain cell markers and function
- No animal cells needed—reduces contamination risk
- Could inform future therapies for dopamine-related disorders
- May help study NR4A2/NURR1-related conditions in a dish
NGFI-B nuclear orphan receptor Nurr1 interacts with p53 and suppresses its transcriptional activity.
Zhang T, Wang P, Ren H, Fan J, Wang G
Nurr1 reduces cell death by blocking the activity of p53, a protein that promotes cell death. This interaction may help protect neurons and could influence diseases involving cell survival, including those related to NR4A2 mutations.
- Nurr1 blocks p53, a key cell death trigger
- This helps protect neurons from dying
- Reduced Nurr1 activity may increase cell death
- May explain neurological symptoms in NR4A2 syndrome
- Suggests potential for therapies targeting p53
Initiation of dopaminergic differentiation of Nurr1(-) mesencephalic precursor cells depends on activation of multiple mitogen-activated protein kinase pathways.
Sabolek M, Baumann B, Heinrich M, Meyer AK, Herborg A, Liebau S, Maisel M, Hermann A, Ventz K, Schwarz J, Wirth T, Storch A
IL-1beta triggers the final development of dopamine-producing brain cells from precursor cells that lack the Nurr1 protein, by activating two specific cellular signaling pathways (ERK1/2 and p38 MAPK), which is essential for turning these cells into functional dopamine neurons.
- IL-1beta drives dopamine neuron development without needing Nurr1
- ERK1/2 and p38 MAPK pathways are critical for this process
- Blocking these pathways stops dopamine neuron formation
- The effect does not involve the usual IL-1 receptor or NF-kappaB
- This reveals a new route to generate dopamine neurons for therapy
[Identification of a possible therapeutic target through pathogenic T cell analysis of multiple sclerosis].
Oki S, Yamamura T
NR4A2 is overactive in immune cells of people with multiple sclerosis and drives the production of inflammatory chemicals that damage the nervous system. Blocking NR4A2 reduces inflammation and prevents disease progression in animal models, suggesting it could be a target for new treatments.
- NR4A2 is highly active in immune cells of MS patients
- It promotes harmful inflammatory chemicals like IL-17 and IFN-gamma
- Reducing NR4A2 activity lowers inflammation and disease severity
- Targeting NR4A2 may lead to new MS treatments
- Findings are supported by both human data and animal models
Identification of transplantable dopamine neuron precursors at different stages of midbrain neurogenesis.
Jönsson ME, Ono Y, Björklund A, Thompson LH
The study identifies the best stage of dopamine neuron development for transplantation: early progenitor cells from the midbrain at embryonic day 10.5 are the most effective at forming dopamine neurons after grafting, while later-stage cells lose this ability. These early cells express Lmx1a and Corin and are found in the ventricular zone, while transplantable cells at later stages are postmitotic neuroblasts expressing Nurr1.
- Best grafts come from midbrain cells at E10.5, not later stages
- Early Lmx1a/Corin+ cells are the main source of dopamine neurons
- Nurr1+ neuroblasts in the intermediate zone are transplantable at E12.5
- TH+ mature neurons do not survive transplantation well
- Corin levels help identify cells that become dopamine neurons
Layer-specific genes reveal a rudimentary laminar pattern in human nodular heterotopia.
Garbelli R, Rossini L, Moroni RF, Watakabe A, Yamamori T, Tassi L, Bramerio M, Russo GL, Frassoni C, Spreafico R
Nodular heterotopia in people with epilepsy show a basic layer-like organization, with genes specific to different brain layers expressed in distinct patterns, suggesting these abnormal tissue clusters are not random but follow a rudimentary blueprint. The surrounding brain tissue also shows disrupted layer-specific gene expression.
- Heterotopia has a basic layer-like structure
- Layer-specific genes are active in correct patterns
- Surrounding brain tissue is abnormal
- Findings suggest developmental origin
- May help explain epilepsy in these patients
Identification of Dlk1, Ptpru and Klhl1 as novel Nurr1 target genes in meso-diencephalic dopamine neurons.
Jacobs FM, van der Linden AJ, Wang Y, von Oerthel L, Sul HS, Burbach JP, Smidt MP
Nurr1 controls key genes that guide the development of dopamine neurons, including Dlk1, Ptpru, and Klhl1, with Dlk1 playing a critical role in delaying dopamine transporter expression until the right stage of neuron maturation. These findings reveal how Nurr1 and Pitx3 work together to shape dopamine neuron formation, which is relevant to understanding NR4A2-related disorders and Parkinson’s disease.
- Nurr1 regulates Dlk1, Ptpru, and Klhl1 in dopamine neurons
- Dlk1 prevents early dopamine transporter expression
- Nurr1 and Pitx3 cooperate to control neuron development
- These genes affect neuron maturation and wiring
- Findings may inform therapies for NR4A2-related conditions
Serotonin 5-HT2C receptor-independent expression of hypothalamic NOR1, a novel modulator of food intake and energy balance, in mice.
Nonogaki K, Kaji T, Ohba Y, Sumii M, Wakameda M, Tamari T
NOR1, a protein in the brain's hunger-regulating center, is reduced in obese mice and helps control eating and weight. Boosting NOR1 reduces food intake and body weight, and this effect happens without involving the serotonin 5-HT2C receptor. This suggests NOR1 could be a new target for treating eating and weight disorders.
- NOR1 levels drop in obese mice
- Increasing NOR1 reduces eating and weight
- NOR1 works independently of serotonin 5-HT2C receptor
- NOR1 is a new regulator of appetite and energy balance
- NOR1 may be a future target for weight-related treatments
Dopamine genes and nicotine dependence in treatment-seeking and community smokers.
Bergen AW, Conti DV, Van Den Berg D, Lee W, Liu J, Li D, Guo N, Mi H, Thomas PD, Lessov-Schlaggar CN, Krasnow R, He Y, Nishita D, Jiang R, McClure JB, Tildesley E, Hops H, Tyndale RF, Benowitz NL, Lerman C, Swan GE
Variants in the NR4A2 gene, which codes for the NURR1 protein, are linked to nicotine dependence, particularly through interactions with the SLC6A3 gene that controls dopamine transport. These genetic findings suggest that NR4A2 plays a role in regulating dopamine-related pathways involved in addiction. The results support the idea that targeting NR4A2 or its interactions could inform treatments for substance use disorders.
- NR4A2 variants are linked to nicotine dependence
- NR4A2 interacts with SLC6A3 to regulate dopamine
- Genetic signals explain about 1% of nicotine dependence variance
- Findings support NR4A2 as a potential therapeutic target
- Results are consistent with known biology of dopamine regulation